Director dealings

RNS Number : 0540J

Ergomed plc

18 August 2021

 

Director Dealings

Guildford, UK - 18 August 2021 : Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that on 17 August 2021, in order to meet demand from new and existing investors, Dr Miroslav Reljanović, Executive Chairman of Ergomed, and Richard Barfield, Chief Financial Officer of Ergomed, sold 1,200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and 50,000 Ordinary Shares respectively at a price of 1200 pence per share.

Following these sales, Dr Miroslav Reljanović holds 9,679,297 Ordinary Shares representing 19.8% of the Company's issued share capital and Richard Barfield holds 50,000 Ordinary Shares representing 0.1% of the Company's issued share capital.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Miroslav Reljanović
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Sale of Shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.00	1,200,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	1,200,000 £12.00 £14,400,000
f)	Date of the transaction	17 August 2021
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Barfield
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Sale of Shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.00	50,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	50,000 £12.00 £600,000
f)	Date of the transaction	17 August 2021
g)	Place of the transaction	London Stock Exchange, AIM

ENDS

Enquiries :

Ergomed plc     Tel: [phone]

Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Numis Securities Limited    Tel: [phone]

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP    Tel: [phone]

James Steel / Dr. Christopher Golden

Consilium Strategic Communications   Tel: [phone]

Chris Gardner / Matthew Neal   [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

END

 

 

DSHGPUQURUPGGGR